Trial Profile
The HALT LTBI study: Phase IV multi-site, unblinded, randomised trial of prophylactic Rifapentine/Isoniazid versus Rifampicin/Isoniazid (Rifinah) for latent tuberculosis infection (LTBI)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Oct 2022
Price :
$35
*
At a glance
- Drugs Isoniazid (Primary) ; Isoniazid/rifampicin (Primary) ; Rifapentine (Primary)
- Indications Tuberculosis
- Focus Therapeutic Use
- Acronyms HALT LTBI
- 02 Mar 2013 New trial record